NO962130L - Synergistisk behandling av Parkinsons sykdom - Google Patents

Synergistisk behandling av Parkinsons sykdom

Info

Publication number
NO962130L
NO962130L NO962130A NO962130A NO962130L NO 962130 L NO962130 L NO 962130L NO 962130 A NO962130 A NO 962130A NO 962130 A NO962130 A NO 962130A NO 962130 L NO962130 L NO 962130L
Authority
NO
Norway
Prior art keywords
disease
parkinson
synergistic treatment
disclosed
combination
Prior art date
Application number
NO962130A
Other languages
English (en)
Other versions
NO962130D0 (no
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO962130D0 publication Critical patent/NO962130D0/no
Publication of NO962130L publication Critical patent/NO962130L/no

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Multimedia (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Det beskrives en fremgangsmåte for behandling av Parkinsons sykdom, hvor et pattedyr som lider av Parkinsons sykdom, behandles med en kombinasjon av en forhjerne-selektiv NMDA-antagonist og en forbindelse som er i stand til å øke den eksitatoriske feedback fra den ventrolaterale kjerne av thalamus inn i cortex. Det beskrives også farmasøytiske blandinger som inneholder den synergistiske kombinasjon.
NO962130A 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom NO962130L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (2)

Publication Number Publication Date
NO962130D0 NO962130D0 (no) 1996-05-24
NO962130L true NO962130L (no) 1996-11-27

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962130A NO962130L (no) 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom

Country Status (26)

Country Link
US (1) US6258827B1 (no)
EP (1) EP0828513B1 (no)
JP (1) JPH11505828A (no)
CN (1) CN1159325A (no)
AT (1) ATE258067T1 (no)
AU (1) AU696258B2 (no)
BR (1) BR9602485A (no)
CA (1) CA2219911C (no)
CO (1) CO4700422A1 (no)
CZ (1) CZ283979B6 (no)
DE (1) DE69532482T2 (no)
DK (1) DK0828513T3 (no)
ES (1) ES2211904T3 (no)
FI (1) FI974323A0 (no)
HU (1) HUP9601419A3 (no)
IL (1) IL118328A (no)
MX (1) MX9709112A (no)
NO (1) NO962130L (no)
NZ (1) NZ286656A (no)
PL (1) PL314413A1 (no)
PT (1) PT828513E (no)
RU (1) RU2176145C2 (no)
SG (1) SG45479A1 (no)
TR (1) TR199600436A2 (no)
TW (1) TW470740B (no)
WO (1) WO1996037226A2 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
IL134363A0 (en) * 1997-10-24 2001-04-30 Warner Lambert Co Method for treating disease-related or drug-induced dyskinesias
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EP1379520B2 (en) 2001-02-23 2014-04-09 Merck Sharp & Dohme Corp. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN100370988C (zh) * 2002-10-08 2008-02-27 阿勒根公司 (2-咪唑啉-2-基氨基)喹噁啉在制备治疗痴呆症和帕金森病的药物中的用途
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1667630A4 (en) * 2003-09-04 2008-07-23 Univ Texas METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASES OF GENITAL AND HARVES, INCLUDING PREMATURE WALKING AND LEIOMYOME
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008526923A (ja) * 2005-01-13 2008-07-24 ノイロサーチ アクティーゼルスカブ 新規８−置換８−アザ−ビシクロ［３．２．１］オクタン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
NO2303330T3 (no) * 2008-06-06 2018-04-14
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
JP6042968B2 (ja) * 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
PT3116475T (pt) 2014-03-13 2020-12-15 Neuroderm Ltd Composições de inibidores de dopa-descarboxilase
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1991012005A1 (en) 1990-02-06 1991-08-22 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
WO1992018502A1 (en) 1991-04-18 1992-10-29 Pfizer Inc. Prodrug esters of phenolic 2-piperidino-1-alkanols
DE4118740A1 (de) 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
HUP9601419A2 (en) 1997-09-29
ES2211904T3 (es) 2004-07-16
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
FI974323A (fi) 1997-11-25
CA2219911A1 (en) 1996-11-28
DK0828513T3 (da) 2004-04-13
ATE258067T1 (de) 2004-02-15
HU9601419D0 (en) 1996-07-29
AU696258B2 (en) 1998-09-03
CO4700422A1 (es) 1998-12-29
NO962130D0 (no) 1996-05-24
EP0828513B1 (en) 2004-01-21
WO1996037226A2 (en) 1996-11-28
MX9709112A (es) 1998-02-28
PL314413A1 (en) 1996-12-09
TW470740B (en) 2002-01-01
DE69532482D1 (de) 2004-02-26
IL118328A0 (en) 1996-09-12
EP0828513A2 (en) 1998-03-18
JPH11505828A (ja) 1999-05-25
US6258827B1 (en) 2001-07-10
CN1159325A (zh) 1997-09-17
BR9602485A (pt) 1998-04-22
DE69532482T2 (de) 2004-11-25
WO1996037226A3 (en) 1996-12-27
AU5451996A (en) 1996-12-05
FI974323A0 (fi) 1997-11-25
NZ286656A (en) 2001-03-30
TR199600436A2 (tr) 1996-12-21
HUP9601419A3 (en) 1998-01-28
CA2219911C (en) 2004-07-27
IL118328A (en) 2001-06-14
CZ283979B6 (cs) 1998-07-15
CZ152496A3 (cs) 1998-04-15
PT828513E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200801805A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BG105534A (en) 5ht1 means and method for the treatment of migraine
NZ502804A (en) 1-(N-(2-substituted phenyl)aminoalkyl)-piperazine derivatives
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
EA199700119A1 (ru) Соединения, оказывающие эффекты на системы, связанные с серотонином
MXPA03010843A (es) Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
MY118944A (en) Synergistic treatment for parkinsonism
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
PT950053E (pt) Novos derivados de benzoilalquil-1,2,3,6-tetra-hidropiridinas
NO951865L (no) Quinuclidin-derivat som substans-P antagonist
FR2718965B1 (fr) Nouvelle application thérapeutique de la spiramycine.
DE69625819T2 (de) Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
ITMI920106A1 (it) Composizioni farmaceutiche comprendenti melatonina o un suo derivato-agonista, atte al trattamento dei disordini cerebro-vascolari
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
MX9803271A (es) Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,6-tetrahid ropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral aminotrofica.